Abstract: Certain anti-viral compounds, pharmaceutical compositions, and methods related thereto are disclosed.

Abstract: Certain anti-viral compounds, pharmaceutical compositions, and methods related thereto are disclosed.

Abstract: Pharmaceutical compositions suitable for long-term storage at room temperature are described. The pharmaceutical composition comprises the compound of formula (I) and can be used for the treatment of steatohepatitis. Also described are methods for preparing the pharmaceutical composition and methods of treatment using the pharmaceutical compositions.

Abstract: Disclosed are crystal of thyroid hormone ? receptor agonist, process for preparing the same and use thereof. The crystal with basically no hygroscopicity, a relatively small crystal particle size and a relatively large drug specific surface area can improve the dissolution rate of drugs, is beneficial to the absorption of drugs and improves the bioavailability.

Abstract: A method for preparing the cyclic phosphonate compound of Formula I is described. The method significantly improves the stereoselectivity of the compound with the required configuration.

Abstract: Pharmaceutical compositions suitable for long-term storage at room temperature are described. The pharmaceutical composition comprises the compound of formula (1) and can be used for the treatment of steatohepatitis. Also described are methods for preparing the pharmaceutical composition and methods of treatment using the pharmaceutical compositions.

Abstract: Certain anti-viral compounds, pharmaceutical compositions, and methods related thereto are disclosed.

Abstract: Certain anti-viral compounds, pharmaceutical compositions, and methods related thereto are disclosed.

Abstract: A pharmaceutical formulation contains the following components in part by weight: (a) 1 part of the compound represented by Formula (I), (b) 16 to 600 parts of a meltable and dispersible carrier comprising poloxamer and polyethylene glycol in a poloxamer-to-polyethylene glycol weight ratio of 1-0.5 to 1:27, and (c) 0.2 to 100 parts of a non-volatile weak acid. The pharmaceutical formulation helps to improve the in vitro dissolution of the compound of Formula (I).

Abstract: Certain anti-viral compounds, pharmaceutical compositions, and methods related thereto are disclosed.

Abstract: A method for preparing the cyclic phosphonate compound of Formula I is described. The method significantly improves the stereoselectivity of the compound with the required configuration.

Abstract: A method for preparing the cyclic phosphonate compound of Formula I is described. The method significantly improves the stereoselectivity of the compound with the required configuration.

Abstract: A pharmaceutical formulation contains the following components in part by weight: (a) 1 part of the compound represented by Formula (I), (b) 16 to 600 parts of a meltable and dispersible carrier comprising poloxamer and polyethylene glycol in a poloxamer-to-polyethylene glycol weight ratio of 1-0.5 to 1:27, and (c) 0.2 to 100 parts of a non-volatile weak acid. The pharmaceutical formulation helps to improve the in vitro dissolution of the compound of Formula (I).

Abstract: The present invention provides a pharmaceutical composition for treating viral hepatitis C, comprising ravidasvir (ASC16) or a pharmaceutically acceptable salt thereof and danoprevir (ASC08) or a pharmaceutically acceptable salt thereof. The combined use of ASC16 and ASC08 has an enhanced effect, and the experimental results show that ASC16 and ASC08 can form an effective combined anti-HCV treatment regimen. Moreover, the administration regimen of ASC16 in combination of ASC08 further expands the action spectrum of therapeutic drugs. More importantly, the combined use of ASC16 and ASC08 solves the problem of drug resistance.

Abstract: The present invention provides methods for improving the pharmacokinetics of protease inhibitors and protease inhibitor precursors and pharmaceutical composition comprising protease inhibitors or protease inhibitor precursors of formula I and a cytochrome P450 monooxigenase inhibitor; when the compound of formula I comprises an amino group, pharmaceutically acceptable ammonium salts thereof, wherein R1 may be, for example, (HO)2P(O)—, (NaO)2P(O)—, alkyl-CO— or cycloalkyl-CO—, wherein X may be, for example, F, Cl, and Br, and wherein R2 and R3 are as defined herein.

Abstract: Angiogenesis, the formation of new blood vessels, is an integral part of normal physiological and developmental processes as well as several pathologies, ranging from tumor growth and metastasis to inflammation and ocular disease. Methods and compositions are provided for controlling normal angiogenesis and for treating angiogenesis associated or mediated diseases as well as for preventing cancer progression and metastasis through the use of a prostrate secretory protein (PSP) family member.

Abstract: Matrix metalloproteinases (MMPs) play an important role in morphogenesis, angiogenesis, wound healing, and in certain disorders such as rheumatoid arthritis, tumor invasion and metastasis. MMPs are thought to be regulated by a variety of cytokines, growth factors, hormones and phorbol esters. This regulation occurs on three levels; alteration of gene expression, activation of the latent zymogen and inhibition by the tissue inhibitors of metalloproteinases (TIMP). We report here a new agent that regulates the level of MMPs.